First-Line Systemic Treatment for Initially Unresectable Colorectal Liver MetastasesMarinde J. G. Bond, Leonie J. Mekenkamp, Koert P. de Jong et al.|JAMA Oncology|2024Cited by 26
LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer GroupCornelis J.A. Punt, R-J. Swijnenburg, Koert P. de Jong et al.|Annals of Oncology|2023Cited by 10
LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer GroupMarinde J. G. Bond, Cornelis J.A. Punt, Helga Droogendijk et al.|Annals of Oncology|2022Cited by 5